<?xml version="1.0" encoding="UTF-8"?>
<p>Current therapies for chronic viral hepatitis include two regimens:
 <list list-type="bullet">
  <list-item>
   <p>IFN or antiviral nucleoside/nucleotide analogues such as lamivudine, adefovir dipivoxil, and ribavirin (Marcellin et al. 
    <xref ref-type="bibr" rid="CR192">2002</xref>; Chander et al. 
    <xref ref-type="bibr" rid="CR24">2002</xref>) and IFN or lamivudine alone can control hepatitis B in about one-third of patients (Marcellin et al. 
    <xref ref-type="bibr" rid="CR192">2002</xref>; Liaw 
    <xref ref-type="bibr" rid="CR102">2002</xref>).
   </p>
  </list-item>
  <list-item>
   <p>A combination of IFN with ribavirin is standard therapy for hepatitis C and has resulted in eradication of HCV in about 50 % of patients (Chander et al. 
    <xref ref-type="bibr" rid="CR24">2002</xref>; McHutchison et al. 
    <xref ref-type="bibr" rid="CR115">1998</xref>).
   </p>
  </list-item>
 </list>
</p>
